Radar · Genomics in San Francisco
Best Genomics Companies in San Francisco, United States
The 149 best Genomics companies in San Francisco, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Insitro.
By Riya SenguptaFinancials
149companies tracked
$6.3Bdisclosed funding
2unicorns
103have raised
FLIAR INTELLIGENCE · GENOMICS × SAN FRANCISCO
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
84%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
3.5Mcombined LinkedIn audience
87%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Genomics companies in San Francisco
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Insitro Developer of machine learning platform for drug discovery and development | $643M | 63 mo ago | 146 146 → 258 (+77%) · sector median +26% | Daphne Koller Founder and CEO | WordPressApple iCloud MailGoogle Workspace+20 | 164 patents AI-driven biomedical data analysis and disease modeling for drug discovery and diagnostics | — |
| 2 | Helix Provider of a genomic database for clinical research | $435M | 60 mo ago | 265 | James Lu CEO | SanityApple iCloud MailNode.js+19 | 48 patents Genomic sequencing data management and cardiac genetic diagnostics for personalized medicine | 2 partnerships |
| 3 | Benchling 🦄 Provider of a cloud-based bioinformatics platform for biotech research | $412M | 55 mo ago | 500 500 → 810 (+62%) · sector median +26% | Ashu Singhal Co-Founder & President | ContentfulApple iCloud MailGoogle Workspace+31 | 15 patents Cloud-based bioprocess workflow and molecular design data management platform. | 1 job opening |
| 4 | BillionToOne 🦄 Provider of cell-free cancer liquid biopsy test | $389M | 24 mo ago | 47 | Oguzhan Atay Co-Founder & CEO | WordPress Block EditorWordPressSentry+20 | 50 patents cfDNA methylation quantification and sequencing assay quality control for diagnostics | 1 launch · 1 partnership · 1 award |
| 5 | Twist Bioscience Developer of a semiconductor-based DNA synthesis platform | $321M | 98 mo ago | 919 919 → 1,302 (+42%) · sector median +26% | Emily Leproust Co-Founder & CEO | Cart FunctionalityAdobe Experience ManagerApple iCloud Mail+34 | 659 patents Synthetic DNA manufacturing, custom nucleic acid libraries, and related hybridization/enzymatic technologies. | — |
| 6 | Encoded Developer of viral gene therapy | $239M | 70 mo ago | 144 144 → 179 (+24%) · sector median +26% | Stephanie Tagliatela Co-Founder And Chief Scientific Officer | WordPressApple iCloud MailGoogle Workspace+25 | — | — |
| 7 | Frontier Medicines Developer of a bioinformatics platform for drug development and chemoproteomics | $236M | 27 mo ago | 119 119 → 78 (-34%) · sector median +26% | Roberto Zoncu Co-Founder | — | 60 patents KRAS G12C mutant inhibition using pyrido‑pyrimidine compounds for cancer therapy | — |
| 8 | Inflammatix Provider of diagnostic solutions for systemic infections 74Funding top 17%Patents top 22%Growth top 26%Innovation top 27% All 10 signals ▾Fundingtop 17% Patentstop 22% Growthtop 26% Innovationtop 27% Moattop 28% Talenttop 35% Techtop 43% Marketbottom 45% Globalbottom 42% Newsbottom 18% Funding: Raised $191M across 11 rounds · 11 rounds over 9 yrs (1.2/yr) Patents: 52 patents matched (strict assignee match) · 36 filings since 2022 vs 16 in 2017-21 rank vs industry peers · Fliar Intelligence Index 74/100 | $191M | 21 mo ago | 54 54 → 75 (+39%) · sector median +26% | Jonathan Romanowsky Co-Founder and Chief Business Officer | WordPressMySQLPHP+24 | 52 patents Patents concentrated in chemistry & materials | 1 launch · 2 partnerships |
| 9 | Invitae Provider of home-based genetic test for individuals | $190M | 62 mo ago | 1,700 | Michele Cargill Co-Founder | ContentfulApple iCloud MailNode.js+22 | 108 patents Computational genomics variant effect prediction and single‑molecule molecular diagnostic assays. | — |
| 10 | Imago BioSciences Developer of epigenetic-based therapies for rare genetic cancers | $160M | 67 mo ago | 27 | — | — | 116 patents KDM1A (LSD1) inhibitor drugs and CAR‑T cell enhancement for hematologic therapies | — |
| 11 | Senti Bio Developer of cell and gene therapies for patients living with incurable diseases 45Product top 14%Funding top 21%Talent top 22%Tech top 32% All 11 signals ▾Producttop 14% Fundingtop 21% Talenttop 22% Techtop 32% Innovationtop 34% Newsbottom 43% Moatbottom 43% Growthbottom 39% Globalbottom 39% Marketbottom 32% Fin. healthbottom 20% Product: 4 distinct product lines · Company stage: Public Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $158M | 1 mo ago | 122 | Jim Collins Co-Founder | DrupalPHPSalesforce+24 | — | — |
| 12 | Atlas Data Provider of cloud-based data storage solutions utilizing DNA as a highly durable, low-cost, and permanent… 29Funding top 26%Moat top 40%Talent bottom 49%Tech bottom 45% All 6 signals ▾Fundingtop 26% Moattop 40% Talentbottom 49% Techbottom 45% Marketbottom 35% Globalbottom 33% Funding: Raised $155M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Moat: Soonicorn · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 29/100 | $155M | 13 mo ago | — | Varun Mehta CEO | WordPress Block EditorWordPressMySQL+19 | — | — |
| 13 | AudentesTherapeutics Developer of therapeutics to treat rare genetic diseases | $138M | 128 mo ago | 404 | — | — | — | — |
| 14 | Seer Developer of proteomics platform for early detection of cancer and neurological diseases | $128M | 70 mo ago | 89 89 → 151 (+70%) · sector median +26% | — | WordPressSentryMySQL+28 | 201 patents Advanced bioanalytical platforms for protein, peptide, and biomolecule detection and characterization | — |
| 15 | Crescendo Bioscience CLIA Laboratory focused on autoimmune and inflammatory diseases | $122M | 161 mo ago | 128 | — | — | — | — |
| 16 | Mission Bio Provider of single cell multiomics platform for genotypic and phenotypic analysis 82Funding top 18%Tech top 21%Innovation top 25%Product top 25% All 10 signals ▾Fundingtop 18% Techtop 21% Innovationtop 25% Producttop 25% Talenttop 28% Moattop 31% Growthtop 37% Markettop 44% Globalbottom 39% Newsbottom 27% Funding: Raised $120M across 11 rounds · 11 rounds over 11 yrs (1.0/yr) Tech: 55 technologies across 6/8 capability areas · Cloud: Cloudflare, Vercel rank vs industry peers · Fliar Intelligence Index 82/100 | $120M | 10 mo ago | 109 109 → 89 (-18%) · sector median +26% | Adam Sciambi Co-Founder & Chief Technology Officer | SanityTurbopackSentry+34 | — | 1 launch · 1 partnership |
| 17 | Veracyte Developer of genomics-based diagnostics for cancer | $113M | 122 mo ago | 815 815 → 722 (-11%) · sector median +26% | — | WordPressApple iCloud MailElasticsearch+29 | 221 patents Molecular diagnostic classifiers for cancer and lung fibrosis using genomic and AI analysis. | 1 launch |
| 18 | uBiome Provider of sequence dataset of human microbiome | $110M | 92 mo ago | 33 | — | — | 320 patents Microbiome sequencing, analysis, and CRISPR-based diagnostics/therapeutics platforms | — |
| 19 | Adela Developer of a platform for detection of cancer 57Funding top 22%Moat top 31%Patents top 38%Talent top 38% All 8 signals ▾Fundingtop 22% Moattop 31% Patentstop 38% Talenttop 38% Markettop 46% Innovationtop 49% Globalbottom 40% Newsbottom 22% Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents rank vs industry peers · Fliar Intelligence Index 57/100 | $109M | 2 mo ago | 62 | Manish Agarwal Co-Founder | — | 15 patents Liquid biopsy nucleic acid extraction and sequencing library preparation technologies | 1 job opening · 1 partnership |
| 20 | Addition Therapeutics Developer of RNA-mediated genetic medicines 42Funding top 22%Talent top 38%Moat top 42%Market bottom 40% All 5 signals ▾Fundingtop 22% Talenttop 38% Moattop 42% Marketbottom 40% Globalbottom 36% Funding: Raised $106M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $106M | 6 mo ago | — | Kathleen Collins Founder | — | — | — |
| 21 | Mirvie Provider of non-invasive diagnostic tests for pregnant women 69Growth top 20%Funding top 21%Patents top 24%Talent top 28% All 9 signals ▾Growthtop 20% Fundingtop 21% Patentstop 24% Talenttop 28% Innovationtop 32% Moattop 36% Techtop 46% Globalbottom 40% Marketbottom 35% Growth: Headcount 23 → 35 (+52%) across vintages · Fresh capital in last 24 mo Funding: Raised $90.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 69/100 | $90M | 11 mo ago | 35 35 → 41 (+17%) · sector median +26% | Mads Melbye Co-Founder | WebflowReactTypekit+21 | 49 patents Non‑invasive prenatal diagnostics via methylation and RNA biomarkers for pregnancy monitoring | — |
| 22 | Rezo AI-powered genomics platform for targeted disease therapeutics | $78M | 47 mo ago | 18 | Jacqueline Fabius Co-Founder | — | — | — |
| 23 | Novome Biotechnologies Developer of gene therapies to treat GI diseases | $77M | 45 mo ago | 44 | Will DeLoache Co-Founder | — | 37 patents Engineered microbial therapeutics and recombinant protein secretion for gut and bile‑acid treatments | — |
| 24 | IgGenix Developer of therapeutic solutions for treating food allergy | $75M | 40 mo ago | 12 | Stephen Quake Co-Founder | WordPress Block EditorWordPressMySQL+14 | 36 patents Peptide-based diagnostics and therapeutics targeting allergic disease prediction and treatment | — |
| 25 | LevitasBio Developer of single-cell imaging and profiling platform based on magnetic levitation technology | $74M | 26 mo ago | 60 | Lars Steinmetz Co-Founder | WordPressMySQLPHP+31 | 29 patents Magnetic/levitation particle separation technologies for biotech and material processing | — |
| 26 | Epicrispr Bio Developer of therapeutics for multiple disease 35Funding top 23%Talent top 38%Moat top 42%Tech bottom 43% All 6 signals ▾Fundingtop 23% Talenttop 38% Moattop 42% Techbottom 43% Globalbottom 37% Marketbottom 32% Funding: Raised $68.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 35/100 | $68M | 14 mo ago | — | Lei Qi Founder | WordPressMySQLPHP+21 | — | — |
| 27 | CODA Biotherapeutics Developer of gene therapy-based analgesics for the treatment of neuropathic pain disorder | $62M | 54 mo ago | 22 | Mitchell H Finer Co-Founder | — | 32 patents Therapeutic peptide/protein compositions targeting neurological disorders. | — |
| 28 | SonoThera Developer of nonviral gene therapies for genetic diseases | $61M | 42 mo ago | 20 | Steve Feinstein Co-Founder | — | 18 patents Ultrasound-enabled delivery systems for therapeutic drugs and nucleic acid therapeutics. | — |
| 29 | 64x Bio Developer of cell lines and production technologies for advanced therapies | $60M | 53 mo ago | 18 18 → 21 (+17%) · sector median +26% | David Thompson Co-Founder | — | — | 2 launchs |
| 30 | Moonwalk Digital platform pioneering precision epigenetic medicines | $57M | 29 mo ago | — | Feng Z Co-Founder | — | — | — |
| 31 | Catalog Technologies Developer of digital information storage system | $54M | 56 mo ago | 11 11 → 14 (+27%) · sector median +26% | Hyunjun Park Co-Founder & CEO | WebflowYouTubecore-js+10 | 22 patents DNA-based data storage systems and methods for encoding, retrieving, and processing information. | — |
| 32 | ReviR Therapeutics Developer of RNA-based therapeutics for multiple diseases 35Funding top 26%AI top 45%Moat top 47%Talent bottom 49% All 8 signals ▾Fundingtop 26% AItop 45% Moattop 47% Talentbottom 49% Marketbottom 36% Globalbottom 36% Techbottom 31% Newsbottom 18% Funding: Raised $54.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) AI: Product described with: machine learning rank vs industry peers · Fliar Intelligence Index 35/100 | $54M | 2 mo ago | 29 | Yang Li Co-Founder | UbuntuElement UIVue.js+6 | — | 1 partnership |
| 33 | Mantra Bio Developer of exosomes to deliver safe, highly targeted medicines | $44M | 41 mo ago | 17 | Terry Gaige Co-Founder And Vp Automation | — | — | — |
| 34 | Siolta Therapeutics Provider of microbiome therapeutics for treating multiple diseases | $42M | 27 mo ago | 14 | Nikole Kimes Founder & CEO | — | — | — |
| 35 | Atomic AI Provider of AI based RNA drug discovery platform | $42M | 40 mo ago | 25 | Raphael Townshend Founder & CEO | WordPress Site EditorWordPressMySQL+11 | 15 patents AI-driven biopolymer/RNA structure prediction and secure data communication protocols | — |
| 36 | Fluidigm Developer of instruments for life sciences industries | $41M | 50 mo ago | 618 618 → 499 (-19%) · sector median +26% | — | — | 647 patents Patents concentrated in transport & manufacturing processes | — |
| 37 | Earli Developer of test to detect and treat early cancer | $40M | 22 mo ago | 38 38 → 36 (-5%) · sector median +26% | Sam Gambhir Co-Founder | WebflowMicrosoft 365jQuery+9 | 29 patents Engineered cancer-specific gene promoters and activatable synthetic biomarkers for targeted diagnostics and therapies | — |
| 38 | Xcell Biosciences Developer of cell culture analysis device for cancer research | $40M | 18 mo ago | 11 11 → 17 (+55%) · sector median +26% | — | WixSentryBootstrap+17 | 30 patents Advanced cell culture bioreactors for tumor microenvironment phenotypic modulation | — |
| 39 | Delve Bio Developer of sequencing platform to detect neuro-infectious pathogens | $35M | 36 mo ago | 2 | Bradley Murray Founder & CEO | — | — | — |
| 40 | Latch Provider of a web-based platform for genomic bioinformatics | $33M | 48 mo ago | 19 | Alfredo Andere Co-Founder & CEO | Node.jsReactNext.js App Router+13 | 29 patents Smart electronic lock hardware and building‑automation integration for access control | — |
| 41 | Cofactor Genomics Developer of diagnostic assays using RNA sequencing 48Funding top 30%Moat top 32%Growth top 35%Tech top 39% All 11 signals ▾Fundingtop 30% Moattop 32% Growthtop 35% Techtop 39% AItop 45% Patentstop 46% Talentbottom 49% Innovationbottom 47% Globalbottom 40% Marketbottom 22% Newsbottom 18% Funding: Raised $26.2M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $26M | 6 mo ago | 9 | Jarret Glasscock Chief Executive Officer | WordPressApple iCloud MailGoogle Workspace+35 | 24 patents Patents concentrated in computing, sensing & instrumentation | — |
| 42 | AnimalBiome Provider of animal microbiome based diagnostics services for pet care | $26M | 21 mo ago | 52 52 → 55 (+6%) · sector median +26% | Holly Ganz Co-Founder & CEO | Shogun Page BuilderCart FunctionalityShopify+50 | — | — |
| 43 | Switchback Systems Provider of synthetic biology platform for a wide range of applications | $18M | 22 mo ago | 5 | Mary Noe CEO and Co-Founder | — | — | — |
| 44 | InsightRx Analytics platform for precision dosing | $13M | 27 mo ago | 19 19 → 31 (+63%) · sector median +26% | — | HubSpot CMS Hubcore-jsPreact+17 | — | — |
| 45 | BacStitch DNA Biotechnology research company specializing in DNA assembly and synthesis | $11M | 15 mo ago | — | Sasha Levy Co-Founder | — | — | — |
| 46 | Kamau Therapeutics Developer of therapeutics for the treatment of genetic diseases | $5M | 13 mo ago | — | Maria Roncarolo Co-Founder | WordPressMySQLPHP+15 | — | — |
| 47 | Alixia Provider of cancer drug discovery and development platform | $2M | 23 mo ago | 5 | Helen Chen Co-Founder & CEO | — | — | — |
| 48 | Duoseq Developer of DNA & RNA-based tumor profiling platform for blood cancers | $2M | 9 mo ago | — | Sandeep Dave Founder & CEO | — | — | — |
| 49 | Gordian Biotechnology Developer of gene therapies to treat diseases of aging | $999K | 13 mo ago | 23 23 → 43 (+87%) · sector median +26% | Francisco LePort Co-Founder & CEO | — | 18 patents In vivo therapeutic screening via single‑nucleus sequencing and viral vector selection | — |
| 50 | GeneTether Developer of Gene editing technologies to treat human diseases | $396K | 17 mo ago | 5 | — | — | 12 patents Targeted gene editing platforms enabling tethered donor DNA delivery for precise genome modifications. | — |
Top 12 Genomics companies in San Francisco
#1
Public · San Francisco, California · founded 2016 · 122 employees$158Mraised▾
Public · San Francisco, California · founded 2016 · 122 employees
Developer of cell and gene therapies for patients living with incurable diseases. The company has developed its proprietary synthetic biology platform to produce cell and gene therapies for cancer treatment. The company's pipeline is comprised of cell therapies engineered with Gene Circuits to target difficult to treat liquid and solid tumors. It offers CAR-NK-based therapies for multiple cancer and tumors.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Product
top 14%Funding
top 21%Talent
top 22%Tech
top 32%Innovation
top 34%News
bottom 43%Product: 4 distinct product lines · Company stage: Public
Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) · Last round Post IPO (May 2026)
Talent: Analyst team rating 5/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 12k LinkedIn followers
Funding rounds
- May 2026Post IPO$40M
- Dec 2024Post IPO$37.6M
- Dec 2024Post IPO$10M
- Jun 2024Grant (prize money)$8M
Founders & team
Investors
Matrix Partners China, Mirae Asset, Ridgeback Capital Management, Lux Capital, Gaingels, KB Investment
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAddthisAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch
#2
Series A · San Francisco, California · founded 2021 · 62 employees$108.5Mraised▾
Series A · San Francisco, California · founded 2021 · 62 employees
Developer of a platform for detection of cancer. The company has developed a blood test for genome-wide methylation analysis technology to detect kidney cancer and intracranial brain tumors. It allows distinguishing the informative methylated regions of the genome from non-informative regions and targets for sequencing.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 22%Moat
top 31%Patents
top 38%Talent
top 38%Market
top 46%Innovation
top 49%Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series A (Apr 2026)
Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents · Soonicorn
Patents: 15 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 6k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Accounts Payable Clerk
Activity (LinkedIn): 1 partnerships announced in 12 mo
Funding rounds
- Apr 2026Series A$5M
- Jun 2025Series A$25.4M
- Jul 2023Series A$48.5M
- Jun 2021Series A$60M
Founders & team
Investors
F-Prime Capital, Orbimed, Deerfield, Decheng Capital, RA Capital Management, LabCorp
#3
Series A · San Francisco, California · founded 2021 · 29 employees$54Mraised▾
Series A · San Francisco, California · founded 2021 · 29 employees
Developer of RNA-based therapeutics for multiple diseases. The company is leveraging machine learning technology and innovative RNA techniques to develop medicines for the treatment of cancer, rare genetic disorders, and infectious diseases.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 26%AI
top 45%Moat
top 47%Talent
bottom 49%Market
bottom 36%Global
bottom 36%Funding: Raised $54.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series A (Apr 2026)
AI: Product described with: machine learning
Moat: Editorial + unicorn rating 3/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. CureCMT) announced in 12 mo
Funding rounds
- Apr 2026Series A—
- Nov 2025Grant (prize money)$4.6M
- Jul 2024Series A$30M
- Jan 2022Seed$20M
Founders & team
Investors
Lapam Capital, CDH, 5Y Capital, Yael Capital, Cmtrf, XtalPi
Tech stack
Core-JsElement UiGoogle WorkspaceLodashNginxSwiper
#4
Series A · San Francisco, California · founded 2021$106.5Mraised▾
Series A · San Francisco, California · founded 2021
Developer of RNA-mediated genetic medicines. The company uses PRINT technology to develop RNA-only therapeutics to transform genetic medicine.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 22%Talent
top 38%Moat
top 42%Market
bottom 40%Global
bottom 36%Funding: Raised $106M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (Dec 2025)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 5k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Alliance for mRNA Medicines (AMM)) announced in 12 mo
Funding rounds
- Dec 2025Series A$106.5M
Founders & team
Investors
SR One, Pivotal Life Sciences, Abingworth, Osage University Partners, Gates, BEVC
#5
Series C · San Francisco, California · founded 2014 · 109 employees$120Mraised▾
Series C · San Francisco, California · founded 2014 · 109 employees
Provider of a single-cell multi-omics platform for genotypic and phenotypic analysis. The company's proprietary Tapestri platform enables the simultaneous detection of analytes, including SNVs, CNVs, and proteins for the precise treatment of cancer. Also, it offers DNA & protein panels, and Pharma Assay Development (PAD) Services.
Fliar Intelligence Index™ 82how this company ranks against its industry peers
Funding
top 18%Tech
top 21%Innovation
top 25%Product
top 25%Talent
top 28%Moat
top 31%Funding: Raised $120M across 11 rounds · 11 rounds over 11 yrs (1.0/yr) · Last round Series C (Aug 2025)
Tech: 55 technologies across 6/8 capability areas · Cloud: Cloudflare, Vercel · Devops: Envoy
Innovation: 6 product lines · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 21k LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. Human Cell Atlas (HCA)) announced in 12 mo
Funding rounds
- Aug 2025Series C—
- Aug 2020Series C$70M
- Oct 2019Grant (prize money)$2M
- Sep 2019Grant (prize money)$1.8M
Founders & team
Investors
Agilent, Cota Capital, Mayfield, Lam Research Capital, LabCorp, NHGRI
Tech stack
Adobe Audience ManagerApple Icloud MailBamboohrBootstrapCloudflareCloudflare Bot Management
#6
Series A · San Francisco, California · founded 2009 · 9 employees$26.2Mraised▾
Series A · San Francisco, California · founded 2009 · 9 employees
Developer of diagnostic assays using RNA sequencing. The company's product includes ImmunoPrism is an RNA sequencing-based assay that uses predictive immune modeling to generate multidimensional biomarkers. It combines machine learning and RNA-sequencing to build gene expression models for immune cells. The company's models for key immune cells include Immune Health Expression Models, Immune Escape Genes, and Co-inhibitory molecules. The company's sequencing products include mRNAble, Total RNAble, picoRNA, FFPExact, miRNAble, RNAccess, RNAmplify, and RNAdvantage.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 30%Moat
top 32%Growth
top 35%Tech
top 39%AI
top 45%Patents
top 46%Funding: Raised $26.2M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) · Last round Series A (Dec 2025)
Moat: Editorial + unicorn rating 7/10 · IP moat: 24 patents · 9 curated direct competitors tracked
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 4k LinkedIn followers
Hiring (LinkedIn): 2 hiring posts in 12 mo (public) · momentum -2 · hiring: Clinical Coordinator, Office Admin
Activity (LinkedIn): 1 partnerships (incl. Labcorp and Ascension Ventures) announced in 12 mo
Funding rounds
- Dec 2025Series A—
- Aug 2023Series A$1.2M
- Dec 2021Series A$6.9M
- Jun 2017Series A$18M
Founders & team
Investors
7percent Ventures, Menlo Ventures, DCVC, Ascension Ventures, Y Combinator, iSelect Fund
Tech stack
AccessibeAmazon S3Amazon Web ServicesApple Icloud MailCloudflareContact Form 7
#7
Series B · San Francisco, California · founded 2019 · 35 employees$90Mraised▾
Series B · San Francisco, California · founded 2019 · 35 employees
Provider of non-invasive diagnostic tests for pregnant women. The company offers blood test-based diagnostics to predict the fetal development and health conditions of prenatal babies. They perform the detection of nine cell-free RNA (cfRNA) which help in measuring the gestational age of the fetal. The other non-invasive tests in which the maternal blood is analyzed for the cRNA to detect the preterm risk management solutions(advance of labor) in women.
Fliar Intelligence Index™ 69how this company ranks against its industry peers
Growth
top 20%Funding
top 21%Patents
top 24%Talent
top 28%Innovation
top 32%Moat
top 36%Growth: Headcount 23 → 35 (+52%) across vintages · Fresh capital in last 24 mo
Funding: Raised $90.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series B (Jul 2025)
Patents: 49 patents matched (strict assignee match) · 41 filings since 2022 vs 8 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 5k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public)
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- Jul 2025Series B$23.7M
- Aug 2023Grant (prize money)$4.6M
- May 2022Conventional Debt—
- May 2022Series B$60M
Founders & team
Investors
Comerica, Decheng Capital, BlackRock, Foresite Capital, General Catalyst, Google Ventures
#8
Seed · San Francisco, California · founded 2025$155Mraised▾
Seed · San Francisco, California · founded 2025
Provider of cloud-based data storage solutions utilizing DNA as a highly durable, low-cost, and permanent data storage medium. It is a company focused on leveraging DNA as a highly durable and permanent data storage medium. As a trailblazer in this emerging field, the company is pushing the boundaries of data storage technology.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 26%Moat
top 40%Talent
bottom 49%Tech
bottom 45%Market
bottom 35%Global
bottom 33%Funding: Raised $155M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (May 2025)
Moat: Soonicorn · 9 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- May 2025Seed$155M
Founders & team
Investors
Arch Venture Partners, Deerfield, Bezos Expeditions, Tao Capital Partners, Earth Foundry, In-Q-Tel
Tech stack
CloudflareCloudflare Bot ManagementContact Form 7Core-JsEwww Image OptimizerGoogle Analytics
#9
Public · San Francisco, California · founded 2015 · 47 employees$388.6Mraised▾
Public · San Francisco, California · founded 2015 · 47 employees
Provider of cell-free cancer liquid biopsy test. The company provides a molecular counter platform to count the DNA molecules from blood samples. It provides genetic tests for cystic fibrosis, spinal muscular atrophy, sickle cell disease, etc.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 42k LinkedIn followers
Activity: 1 product launches · 1 partnerships · 1 awards (incl. four largest commercial insurers in the U.S.) announced in 12 mo
Funding rounds
- Jun 2024Series D$130M
- Dec 2022Conventional Debt—
- Dec 2022Series C$48.5M
- Mar 2022Series C$125M
Founders & team
Investors
500 Global, Hummingbird Ventures, Neotribe, Libertus Capital, Pacific 8 Ventures, Y Combinator
Tech stack
Apple Icloud MailCdnjsCloudflareCookieyesGoogle AnalyticsGoogle Font Api
#10
Series E · San Francisco, California · founded 2016 · 54 employees$191.5Mraised▾
Series E · San Francisco, California · founded 2016 · 54 employees
Provider of diagnostic solutions for systemic infections. Its proprietary technology, based on research from Stanford University, measures gene expression patterns related to the immune system to diagnose sepsis. It provides products such as InSep for acute infection and sepsis tests, ViraBac for acute infection tests, SARC-CoV-2 swabs, etc.
Fliar Intelligence Index™ 74how this company ranks against its industry peers
Funding
top 17%Patents
top 22%Growth
top 26%Innovation
top 27%Moat
top 28%Talent
top 35%Funding: Raised $191M across 11 rounds · 11 rounds over 9 yrs (1.2/yr) · Last round Series E (Sep 2024)
Patents: 52 patents matched (strict assignee match) · 36 filings since 2022 vs 16 in 2017-21 · Latest publication 2026
Growth: Headcount 30 → 54 (+80%) across vintages · Fresh capital in last 24 mo
Audience (LinkedIn): 10k LinkedIn followers
Activity (LinkedIn): 1 product launches · 2 partnerships (incl. University of Nebraska Medical Center and the National Quarantine Unit) announced in 12 mo
Funding rounds
- Sep 2024Series E$57M
- Jul 2023Grant (prize money)$299.8K
- Nov 2021Grant (prize money)$12.1M
- Nov 2021Grant (prize money)$1.7M
Founders & team
Investors
GSVP, Khosla Ventures, Think.Health, Northpond Ventures, StartX, DARPA
Tech stack
BootstrapBricksCloudflareCloudflare Bot ManagementContact Form 7Core-Js
#11
Series B · San Francisco, California · founded 2018$68Mraised▾
Series B · San Francisco, California · founded 2018
Developer of therapeutics for multiple diseases. It offers gene therapies using ultracompact Cas proteins which modulate gene expression without cutting DNA. The company's platform leverages the power of CRISPR/Cas9 gene editing to target specific genes and achieve therapeutic outcomes. The pipeline includes EPI-321 for facioscapulohumeral muscular dystrophy, EPI-221, EPI-224 for genetic disorder, EPI 114 and EPI 111 for petinas pigmentosa.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 23%Talent
top 38%Moat
top 42%Tech
bottom 43%Global
bottom 37%Market
bottom 32%Funding: Raised $68.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (Mar 2025)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 7k LinkedIn followers
Funding rounds
- Mar 2025Series B$68M
Founders & team
Investors
Ally Bridge Group, Solve FSHD, LDV Partners
#12
Series B · San Francisco, California · founded 2012 · 11 employees$39.5Mraised▾
Series B · San Francisco, California · founded 2012 · 11 employees
Developer of cell culture analysis device for cancer research. The platform technology Avatar mimics in vivo physiological conditions for reproducible and more accurate in vitro tests. It allows for the preferential isolation and expansion of circulating tumor cells in the patient's blood. The company also provides cell-binding substrates and culture media to use in conjunction with its platform. The company has developed a cell analysis tool which is AI enables and assists with real-time analysis of cell health for identifying cell kinetics, targets, and other immunotherapy research.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 7k LinkedIn followers
Funding rounds
- Dec 2024Series B$1.4M
- Jan 2022Series B$27.5M
- Feb 2017Series A$12M
- Jul 2015Seed—
Investors
HBM Genomics, Illumina, Casdin Capital, Dynamk Capital, Formic Ventures, LabCorp
Tech stack
BootstrapCloudflareCloudflare Bot ManagementGodaddyGoogle AnalyticsGoogle Cloud
Funding & investor landscape
$6.3Btotal disclosed funding
99companies funded
337disclosed rounds
3rounds last 90 days
Most active investors
Notable founders
Jim Collins
Co-Founder · Senti Bio
Wilson Wong
Co-Founder · Senti Bio
Manish Agarwal
Co-Founder · Adela
Scott Bratman
Co-Founder · Adela
Yang Li
Co-Founder · ReviR Therapeutics
Kathleen Collins
Founder · Addition Therapeutics
Ron Park
CEO · Addition Therapeutics
Adam Sciambi
Co-Founder & Chief Technology Officer · Mission Bio
Charlie Silver
Co-Founder · Mission Bio
Jarret Glasscock
Chief Executive Officer · Cofactor Genomics
Mads Melbye
Co-Founder · Mirvie
Maneesh Jain
Co-Founder & CEO · Mirvie
Prism market signals · United States · country-scoped Prism corpus, 1,273,702 docs
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Bioinformatics is moving in the United States
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,110 United States-affiliated papers.
research sentiment over time
200820182029
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 41% → 46% across 2008–2029.
top research entities
- Harvard University633
- Broad Institute433
- Howard Hughes Medical Institute318
- Stanford University287
- Johns Hopkins University287
leading researchers
Glen Charles Ritschel · Claude · Stylianos Chatzimanolis · Giannis Bolanakis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Yue Ma
▲
Breakthroughs5,029 · 38%
▼ 39%→38% share
▲1.0× share momentum0 median citations85% since 2021mostly methods-led
Transcriptome breakthroughs are surging — U.S. papers jumped from 25 to 436, with Interpretability newly emerging at 50 papers.
rising sub-themes (early→recent)
- Gene83→532
- Transcriptome25→436
- Genome117→419
- Disease6→218
- Immune system11→219
Newly emergingPattern recognition (psychology) 0→57 · Interpretability 0→50 · Limiting 0→47
Landmark Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 · 97,164 cites
◆
Advancements3,749 · 29%
▲ 21%→30% share
▲1.4× share momentum0 median citations90% since 2021mostly empirical
Biomarker advancements are intensifying — papers rose from 2 to 208, alongside newly emerging Precision medicine research at 86 papers.
rising sub-themes (early→recent)
- Disease17→407
- Immune system4→266
- Gene38→281
- Transcriptome13→238
- Biomarker2→208
Newly emergingPrecision medicine 0→86 · Pathogenesis 0→49 · Receptor 0→42
Landmark limma powers differential expression analyses for RNA-sequencing and microarray studies · 41,828 cites
▼
Concerns2,105 · 16%
▼ 18%→16% share
▼0.9× share momentum0 median citations85% since 2021mostly reviews
Clinical-trial concern research is rising sharply — papers grew from 4 to 111, with Immunotherapy concerns newly emerging at 56 papers.
rising sub-themes (early→recent)
- Disease27→311
- Immune system6→152
- Cancer17→130
- Clinical trial4→111
- Biomarker2→92
Newly emergingImmunotherapy 0→56 · Narrative review 0→36 · Mutation 0→33
Landmark The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia · 10,090 cites
RESEARCH HOTSPOTS · United States
Where bioinformatics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston1143 · +0.51
New York807 · +0.46
SF Bay Area683 · +0.57
Philadelphia330 · +0.44
San Diego298 · +0.56
Los Angeles287 · +0.42
Chicago284 · +0.51
Seattle244 · +0.54
Ann Arbor218 · +0.45
Atlanta215 · +0.44
PATENT SIGNAL · United States
Who's filing bioinformatics patents in the United States
United States bioinformatics patent filing is accelerating — 246 filings from 64 assignees (2016–2025), led by Edico Genome, Illumina, UNIV Washington; annual filings 22→23.
246 filings64 assigneespeak 44/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Edico Genome129
- Illumina60
- UNIV Washington18
- Nantomics9
- Genomsys7
- Baluch Mohamed Khoso7
- Microsoft6
- Contamination Source Identificat6
Common questions
How many Genomics companies are there in San Francisco, United States?
Radar tracks 149 indexable Genomics companies headquartered in San Francisco, United States that meet our profile-completeness bar.
What is the total funding raised by Genomics companies in San Francisco, United States?
The Genomics companies in San Francisco, United States on this list have raised a combined $6.3B in disclosed equity funding across 99 funded companies.
Which is the highest-funded Genomics company in San Francisco, United States?
Insitro is the highest-funded Genomics company in San Francisco, United States, with $643.2M in disclosed equity funding.
How many Genomics companies in San Francisco, United States are funded?
99 of the 149 Genomics companies in San Francisco, United States on this list have disclosed at least one equity funding round.
How many Genomics unicorns are there in San Francisco, United States?
2 Genomics companies in San Francisco, United States on this list are valued at $1B or more.
Who are the top investors in San Francisco, United States Genomics companies?
The most active investors in San Francisco, United States Genomics companies on this list include HHS, Y Combinator, IndieBio, JLABS, Illumina.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.